Atrium Therapeutics (RNA) Q3 2026: BMS Milestone Drives Narrowest Loss in Two Years

A $15.0 million milestone payment from Bristol Myers Squibb under Atrium's research collaboration and license agreement did most of the heavy lifting in Q3 2026, driving collaboration revenue to $15.32 million. That figure beat expectations and lifted total revenue 22.8% from the same quarter a year earlier.

The milestone also compressed the quarterly loss to its tightest level in at least two years. GAAP EPS came in at negative $0.25, beating expectations. Atrium had reported losses of $0.97 and $1.18 in the two preceding quarters, a dramatic improvement.

Rising costs are the other side of the ledger. R&D expense climbed to roughly $13.80 million, driven by the launch of Corventis, Atrium's Phase 1/2 trial of ATR 1072 in PRKAG2 syndrome. G&A expense expanded as well, reflecting employee-related expenses, professional fees, and the broader costs of operating as a standalone public company.

On the balance sheet, pro-forma cash stands at $293.6 million following an October private placement that raised $50.0 million from institutional investors. That compares to a market cap of roughly $128 million, meaning Atrium's cash alone exceeds its market value. Management says the runway extends through 2028, comfortably past the first Corventis proof-of-concept data expected in the second half of 2027.

The pipeline outlook adds further catalysts to the timeline. Beyond Corventis, Atrium plans to file an IND for ATR 1086 in PLN cardiomyopathy in 2027 and expects to select its next development candidate from two undisclosed rare cardiomyopathy programs in the same year. CEO Kathleen Gallagher described the Corventis initiation as the first clinical trial ever to target the root cause of PRKAG2 syndrome, a disease for which no approved therapy currently addresses the underlying genetic driver.